Last reviewed · How we verify
Glargine and Lispro insulin — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Glargine and Lispro insulin (Glargine and Lispro insulin) — Universidad de Guanajuato.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Glargine and Lispro insulin TARGET | Glargine and Lispro insulin | Universidad de Guanajuato | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Glargine and Lispro insulin CI watch — RSS
- Glargine and Lispro insulin CI watch — Atom
- Glargine and Lispro insulin CI watch — JSON
- Glargine and Lispro insulin alone — RSS
Cite this brief
Drug Landscape (2026). Glargine and Lispro insulin — Competitive Intelligence Brief. https://druglandscape.com/ci/glargine-and-lispro-insulin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab